Abstract
Studies in children and adults revealed cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine (CAIV-T) to be well accepted, well tolerated and highly protective against culture-confirmed influenza, and to provide significant health benefits. A 2 year, multicentre, double-blind, placebo-controlled efficacy field trial of CAIV-T in children aged 15-71 months with annual re-immunization revealed the vaccine to be highly protective against culture-confirmed influenza. Vaccine induced serum and secretory antibodies in vaccinated children. Overall, during 2 years of study, vaccine was 92% protective against culture-confirmed influenza. During the second year of study the vaccine was 86% protective against influenza A/Sydney/5/97-like virus, a significantly drifted strain not well matched to the vaccine. Antibody studies on children given CAIV-T revealed that high titres of cross-reacting antibodies to influenza A/Sydney/5/97 were induced with vaccination by live attenuated influenza A/Wuhan/359/95-like vaccine. Effectiveness measures revealed significant reductions in febrile illness (21% reduction in year 1, 19% reduction in year 2), febrile otitis media (33% reduction in year 1, 16% reduction in year 2) and associated antibiotic use among vaccinated children compared with placebo recipients. In adults, vaccination with CAIV-T resulted in protection during experimental challenge with virulent wild-type viruses. An effectiveness trial in adults demonstrated significant benefits of CAIV-T vaccine (28% reduction in days of missed work for febrile upper respiratory illness days with associated 45% reduction in days taking antibiotics). General use of CAIV-T has the potential to significantly reduce the impact of influenza in children and adults.
Full Text
The Full Text of this article is available as a PDF (135.5 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Belshe R. B., Gruber W. C., Mendelman P. M., Cho I., Reisinger K., Block S. L., Wittes J., Iacuzio D., Piedra P., Treanor J. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 2000 Feb;136(2):168–175. doi: 10.1016/s0022-3476(00)70097-7. [DOI] [PubMed] [Google Scholar]
- Belshe R. B., Gruber W. C., Mendelman P. M., Mehta H. B., Mahmood K., Reisinger K., Treanor J., Zangwill K., Hayden F. G., Bernstein D. I. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis. 2000 Mar;181(3):1133–1137. doi: 10.1086/315323. [DOI] [PubMed] [Google Scholar]
- Belshe R. B., Gruber W. C. Prevention of otitis media in children with live attenuated influenza vaccine given intranasally. Pediatr Infect Dis J. 2000 May;19(5 Suppl):S66–S71. doi: 10.1097/00006454-200005001-00010. [DOI] [PubMed] [Google Scholar]
- Belshe R. B., Swierkosz E. M., Anderson E. L., Newman F. K., Nugent S. L., Maassab H. F. Immunization of infants and young children with live attenuated trivalent cold-recombinant influenza A H1N1, H3N2, and B vaccine. J Infect Dis. 1992 Apr;165(4):727–732. doi: 10.1093/infdis/165.4.727. [DOI] [PubMed] [Google Scholar]
- Boyce T. G., Gruber W. C., Coleman-Dockery S. D., Sannella E. C., Reed G. W., Wolff M., Wright P. F. Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine. 1999 Aug 20;18(1-2):82–88. doi: 10.1016/s0264-410x(99)00183-8. [DOI] [PubMed] [Google Scholar]
- Chonmaitree T., Owen M. J., Patel J. A., Hedgpeth D., Horlick D., Howie V. M. Effect of viral respiratory tract infection on outcome of acute otitis media. J Pediatr. 1992 Jun;120(6):856–862. doi: 10.1016/s0022-3476(05)81950-x. [DOI] [PubMed] [Google Scholar]
- Heikkinen T., Thint M., Chonmaitree T. Prevalence of various respiratory viruses in the middle ear during acute otitis media. N Engl J Med. 1999 Jan 28;340(4):260–264. doi: 10.1056/NEJM199901283400402. [DOI] [PubMed] [Google Scholar]
- Henderson F. W., Collier A. M., Sanyal M. A., Watkins J. M., Fairclough D. L., Clyde W. A., Jr, Denny F. W. A longitudinal study of respiratory viruses and bacteria in the etiology of acute otitis media with effusion. N Engl J Med. 1982 Jun 10;306(23):1377–1383. doi: 10.1056/NEJM198206103062301. [DOI] [PubMed] [Google Scholar]
- Nichol K. L., Mendelman P. M., Mallon K. P., Jackson L. A., Gorse G. J., Belshe R. B., Glezen W. P., Wittes J. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA. 1999 Jul 14;282(2):137–144. doi: 10.1001/jama.282.2.137. [DOI] [PubMed] [Google Scholar]
- Swierkosz E. M., Newman F. K., Anderson E. L., Nugent S. L., Mills G. B., Belshe R. B. Multidose, live attenuated, cold-recombinant, trivalent influenza vaccine in infants and young children. J Infect Dis. 1994 May;169(5):1121–1124. doi: 10.1093/infdis/169.5.1121. [DOI] [PubMed] [Google Scholar]
- Treanor J. J., Kotloff K., Betts R. F., Belshe R., Newman F., Iacuzio D., Wittes J., Bryant M. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine. 1999 Dec 10;18(9-10):899–906. doi: 10.1016/s0264-410x(99)00334-5. [DOI] [PubMed] [Google Scholar]